Maravai LifeSciences (NASDAQ: MRVI) net income
Maravai LifeSciences reported a net loss of $130.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $144.8m. Earnings per share were −$0.90.
Maravai LifeSciences's best year of the last 6 was fiscal 2022. It reported a loss in 3 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$130.8m | — | −70.4% | −$0.90 |
| 2024 | −$144.8m | — | −55.9% | −$1.05 |
| 2023 | −$119.0m | −154.1% | −41.2% | −$0.90 |
| 2022 | $220.2m | +21.0% | 24.9% | $1.67 |
| 2021 | $182.0m | +104.6% | 22.8% | $1.59 |
| 2020 | $89.0m | — | 31.3% | $7.43 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Maravai LifeSciences net income compared with its sector
By net income for its latest fiscal year, Maravai LifeSciences ranks 365th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Maravai LifeSciences, −70.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 363rd | Protagonist Therapeutics | −$130.1m | −282.8% |
| 364th | Cartesian Therapeutics | −$130.3m | −4,658.6% |
| 365th | Maravai LifeSciences | −$130.8m | −70.4% |
| 366th | Kestra Medical Technologies | −$131.6m | −138.4% |
| 367th | NovoCure | −$136.2m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Maravai LifeSciences
- How much did Maravai LifeSciences earn in fiscal 2025?
- Maravai LifeSciences reported a net loss of $130.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $144.8m.
- What are the earnings per share of Maravai LifeSciences?
- They were −$0.90 in fiscal 2025, compared with −$1.05 in fiscal 2024.
- What was the most profitable year for Maravai LifeSciences?
- Of its last 6 fiscal years, fiscal 2022, with $220.2m.
- Where does Maravai LifeSciences rank in its sector by net income?
- It ranks 365th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Maravai LifeSciences come from?
- From the annual report (Form 10-K) that Maravai LifeSciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Maravai LifeSciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Maravai LifeSciences: the Maravai LifeSciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.